Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a co-packaged therapeutic kit containing a combination of **Esomeprazole** (a Proton Pump Inhibitor), **Amoxicillin** (a penicillin antibiotic), and **Clarithromycin** (a macrolide antibiotic). It is designed for the eradication of *Helicobacter pylori*.
## Primary Indications
Treatment of *Helicobacter pylori* infection in patients with duodenal ulcer disease or chronic gastritis to reduce the risk of duodenal ulcer recurrence.
## Adult Dosing
Standard regimen consists of the following taken twice daily (BID) for 7 to 14 days:
* **Esomeprazole:** 40 mg BID
* **Amoxicillin:** 1000 mg BID
* **Clarithromycin:** 500 mg BID
* *Note: Always verify specific kit composition, as packaging variations exist by region.*
## Pediatric Dosing
**Not indicated.** Safety and efficacy have not been established in pediatric populations. Use is generally avoided due to the clarithromycin component and potential for antibiotic resistance.
## Dose Adjustments
* **Renal Impairment:** No adjustment required for Esomeprazole. Significant caution with Amoxicillin/Clarithromycin; dose reduction or extended intervals may be required for severe renal impairment (CrCl < 30 mL/min).
* **Hepatic Impairment:** Generally avoid in patients with severe hepatic impairment due to the clearance profiles of clarithromycin and esomeprazole. Use with caution in mild-to-moderate impairment.
## Contraindications
* Known hypersensitivity to esomeprazole, amoxicillin, clarithromycin, or any component of the formulation.
* Concomitant use with cisapride, pimozide, astemizole, or terfenadine due to life-threatening QT prolongation/cardiac arrhythmias (via CYP3A4 inhibition by clarithromycin).
* History of cholestatic jaundice or hepatic dysfunction associated with previous use of clarithromycin.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, abdominal pain, altered taste (dysgeusia), headache.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe cutaneous adverse reactions (SCARs like SJS/TEN), anaphylaxis, transient QT prolongation, and acute interstitial nephritis.
## Key Drug Interactions
* **CYP3A4 Substrates:** Clarithromycin is a potent inhibitor; significantly increases serum levels of statins (atorvastatin, simvastatin), colchicine, and benzodiazepines.
* **pH-Dependent Absorption:** Esomeprazole may decrease the absorption of drugs like atazanavir, nelfinavir, and ketoconazole.
* **Anticoagulants:** Monitor INR closely with warfarin as clarithromycin may potentiate effects.
* **Methotrexate:** PPIs may increase methotrexate levels.
## Monitoring
* Monitor for signs of *C. difficile* infection (persistent diarrhea).
* Assess for resolution of *H. pylori* via urea breath test or fecal antigen test 4 weeks after completion of therapy.
* Monitor ECG if patient is on other QT-prolonging agents.
* Monitor CBC and LFTs if therapy duration exceeds 14 days.
## Clinical Pearls
* **Adherence:** High pill burden requires thorough patient counseling; non-adherence is the primary cause of treatment failure.
* **Administration:** Esomeprazole should be taken at least 60 minutes before a meal. Amoxicillin and Clarithromycin can be taken with or without food.
* **Resistance:** Clarithromycin-resistant *H. pylori* is increasing globally; if eradication fails, susceptibility testing or alternate regimens (e.g., bismuth-based quadruple therapy) may be necessary.
* **Allergy:** Verify absence of penicillin allergy before initiating therapy.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practices vary by institution and region. Always verify specific dosing, safety information, and contraindications by consulting the official FDA-approved prescribing information or your local formulary.
